| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
2013
|
5 |
1 |
p. 95-95
|
artikel
|
| 2 |
Combining Notch inhibition with current therapies for breast cancer treatment
|
Brennan, Keith
|
|
2013
|
5 |
1 |
p. 17-24
|
artikel
|
| 3 |
Immunotherapy updates in pancreatic cancer: are we there yet?
|
Gunturu, Krishna Soujanya
|
|
2013
|
5 |
1 |
p. 81-89
|
artikel
|
| 4 |
New agents on the horizon in hepatocellular carcinoma
|
Zhu, Andrew X.
|
|
2013
|
5 |
1 |
p. 41-50
|
artikel
|
| 5 |
New treatment approaches in melanoma: current research and clinical prospects
|
Rughani, Milap G.
|
|
2013
|
5 |
1 |
p. 73-80
|
artikel
|
| 6 |
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients
|
Deenen, Maarten J.
|
|
2013
|
5 |
1 |
p. 91-92
|
artikel
|
| 7 |
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?
|
Troiani, Teresa
|
|
2013
|
5 |
1 |
p. 51-72
|
artikel
|
| 8 |
Targeted therapies in medical oncology: successes, failures and next steps
|
Mallarkey, Gordon
|
|
2013
|
5 |
1 |
p. 5-16
|
artikel
|
| 9 |
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle
|
Cubero, Daniel I. G.
|
|
2013
|
5 |
1 |
p. 93-94
|
artikel
|
| 10 |
The changing landscape in the treatment of metastatic castration-resistant prostate cancer
|
El-Amm, Joelle
|
|
2013
|
5 |
1 |
p. 25-40
|
artikel
|
Tijdschrift beschrijving